Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2
| Autor: | Schluckebier, Luciene, Garay, Osvaldo U., Zukin, Mauro, Ferreira, Carlos G. |
|---|---|
| Zdroj: | In Lung Cancer September 2015 89(3):274-279 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect